MX2023006736A - Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr. - Google Patents

Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr.

Info

Publication number
MX2023006736A
MX2023006736A MX2023006736A MX2023006736A MX2023006736A MX 2023006736 A MX2023006736 A MX 2023006736A MX 2023006736 A MX2023006736 A MX 2023006736A MX 2023006736 A MX2023006736 A MX 2023006736A MX 2023006736 A MX2023006736 A MX 2023006736A
Authority
MX
Mexico
Prior art keywords
methods
blood glucose
body weight
reduce blood
therapeutic regimes
Prior art date
Application number
MX2023006736A
Other languages
English (en)
Spanish (es)
Inventor
Joyce James
Omar Olhaye
Vyjayanthi Krishnan
Matthew Scott Harris
Original Assignee
Spitfire Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spitfire Pharma Llc filed Critical Spitfire Pharma Llc
Publication of MX2023006736A publication Critical patent/MX2023006736A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023006736A 2020-12-07 2021-12-07 Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr. MX2023006736A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063122117P 2020-12-07 2020-12-07
US202163211157P 2021-06-16 2021-06-16
US202163249468P 2021-09-28 2021-09-28
PCT/US2021/062286 WO2022125598A1 (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Publications (1)

Publication Number Publication Date
MX2023006736A true MX2023006736A (es) 2023-08-21

Family

ID=81972768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006736A MX2023006736A (es) 2020-12-07 2021-12-07 Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr.

Country Status (8)

Country Link
US (1) US20250134963A1 (https=)
EP (1) EP4255564A4 (https=)
JP (1) JP2024500324A (https=)
KR (1) KR20230129425A (https=)
CA (1) CA3201539A1 (https=)
IL (1) IL303512A (https=)
MX (1) MX2023006736A (https=)
WO (1) WO2022125598A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269238A1 (en) * 2022-09-14 2024-08-15 Spitfire Pharma Llc Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
JP2025537192A (ja) * 2022-11-05 2025-11-14 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法
WO2025098416A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于减肥的glp-1化合物
WO2025193765A1 (en) * 2024-03-12 2025-09-18 Spitfire Pharma Llc Therapeutic regimens and methods for reducing body weight and/or serum lipids using a glp-1r and gcgr agonist
CN118477048B (zh) * 2024-05-24 2024-12-17 山东泰合医药科技有限公司 一种布瑞哌唑缓释微球及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
PT3155017T (pt) * 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
ES2983409T3 (es) * 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
EP4506017A3 (en) * 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations

Also Published As

Publication number Publication date
CA3201539A1 (en) 2022-06-16
WO2022125598A1 (en) 2022-06-16
JP2024500324A (ja) 2024-01-09
KR20230129425A (ko) 2023-09-08
IL303512A (en) 2023-08-01
EP4255564A4 (en) 2024-11-06
EP4255564A1 (en) 2023-10-11
US20250134963A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
MX2023006736A (es) Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr.
Chang et al. Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides: endogenous 5-HT2C receptors in choroid plexus epithelial cells
CN109476723B (zh) Ny-eso-1肿瘤抗原hla-a*02复合物的特异性t细胞受体
Wu et al. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells
Kim et al. System L-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells
CL2020003237A1 (es) Proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) (divisional de la solicitud no. 201801695)
AU2016255611A1 (en) T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR)
MA42037B1 (fr) Protéines de fusion
KR20240095310A (ko) 당뇨병을 위한 gip/glp1 공효능제의 사용 방법
WO2009010968A3 (en) Disease treatment via antimicrobial peptides or their inhibitors
Cui et al. The endoplasmic reticulum stress response: a link with tuberculosis?
US20220185865A1 (en) Mhc class ia open conformers
MX2025003002A (es) Regímenes terapéuticos y métodos para reducir peso corporal en un sujeto con enfermedad de hígado graso usando un agonista de glp-1r y gcgr
CN108779164B (zh) Hla-b57开放型构象异构体
Tjong et al. The role of the RGD motif in CD97/ADGRE5-and EMR2/ADGRE2-modulated tumor angiogenesis
MX2022016087A (es) Anticuerpos que unen el tgf-alfa y la epirregulina para su uso en el tratamiento del dolor.
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
Sonavane et al. Controlling Wnt signaling specificity and implications for targeting WNTs pharmacologically
CN112585159A (zh) 神经调节蛋白多肽片段及其用途
Minguet et al. The extracellular part of ζ is buried in the T cell antigen receptor complex
MX2025005071A (es) Regímenes terapéticos y métodos para el tratamiento de factores de riesgo cardiovascular utilizando un agonista del glp-1r y del gcgr
Wahlsten et al. Separation of function between the domains of toxic shock syndrome toxin-1
US10722553B2 (en) Medicament containing recombinant mistletoe lectins for the treatment of brain tumors
Cervigón-González et al. Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox
Tao et al. Molecular cloning, recombinant expression and characterization of GMCSF from the rhesus monkey, Macaca mulatta